News - Gilde Healthcare

Latest news

Latest news

Latest news
Venture&Growth

Latest news
Private Equity

Latest news
Climate Solutions

Gilde Healthcare company CatalYm announces first patient dosed in Phase 2b trial evaluating Visugromab in combination with chemoimmunotherapy as frst-line treatment in Metastatic Non-squamous NSCLC

CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company’s anti-GDF-15 antibody...

30 September 2025

Gilde Healthcare company CatalYm announces first patient dosed in Phase 2b trial evaluating Visugromab in combination with chemoimmunotherapy as frst-line treatment in Metastatic Non-squamous NSCLC

CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company’s anti-GDF-15 antibody...

30 September 2025

Gilde Healthcare appoints Dr. Christian Stark as Group CEO of its globally operating medical technology group

The medical technology group, which includes two manufacturers of surgical instruments in the Tuttlingen region, Koscher & Würtz and Christian Diener, has appointed Dr. Christian Stark as Chief Executive Officer...

3 September 2025

Gilde Healthcare company CatalYm announces first patient dosed in Phase 2b trial evaluating Visugromab in combination with chemoimmunotherapy as frst-line treatment in Metastatic Non-squamous NSCLC

CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company’s anti-GDF-15 antibody...

30 September 2025

Filter & search

Search:
Loading...
These were all articles
51bbaa7cad